Founded in 2013, Guelph-based NuBiyota develops microbiome therapeutics designed to restore gut balance, using multi-strain microbial compositions delivered as drug products. The company’s Microbial Ecosystem Therapeutics platform grew from University of Guelph research led by co-founder Dr. Emma Allen-Vercoe and supports four clinical-stage candidates. NuBiyota conducts research in Guelph and operates a GMP manufacturing hub in Pearl River, New York, with a strategic collaboration with Takeda for gastrointestinal indications.
Allied MicrobiotaAllied Microbiota grew out of a Columbia University microbiology lab and was founded in 2017 by environmental microbiologist Ray Sambrotto. The Stony Brook company develops FastBac microbial treatments for organizations facing difficult environmental cleanup challenges, with its research focused on turning naturally occurring microbes into scalable bioremediation tools.STONY BROOK, NY
Biosortia MicrobiomicsFounded by inventor Ross O. Youngs, Biosortia Microbiomics is a Columbus, Ohio company known for turning microbial-community chemistry into drug-discovery opportunities. Youngs brings nearly four decades of invention and more than 75 worldwide patents to a team led by pharmaceutical natural-products scientists, while the company’s Industrial-Scale Microbiome Mining platform gives researchers access to compounds that conventional small samples can miss. Its current lead focus is gut-restricted discovery for obesity and metabolic health.COLUMBUS, OH
Aquavit Pharmaceuticals, IncFounded in New York City in 2010, Aquavit Pharmaceuticals is a biotechnology company known for developing personalized healthcare through modern drug-delivery systems. Its patented micro-channel platform is designed to deliver therapeutic agents directly into the skin, supporting more targeted treatment while minimizing systemic toxicity. Aquavit has commercialized AQUAGOLD® and maintains an intellectual-property portfolio of more than 30 patents and 25 trademarks.NEW YORK, NY
Fzata, IncFzata, Inc. is a Maryland biotechnology company founded by scientists whose research focuses on C. difficile infection and the gut’s immune response. The near-clinical-stage company develops oral biologic medicines for gastrointestinal and immune-related disease, using its BioPYM platform to deliver treatments directly in the gut. Its work has attracted more than $24 million in non-dilutive NIH funding.HALETHORPE, MD